Lercanidipine – 5 reasons why it is worth to use it Review article
Article Sidebar
Published:
Mar 31, 2015
Keywords:
lercanidipine, arterial hypertension, calcium antagonist
Main Article Content
Abstract
Calcium antagonists are widely used class of drugs in the treatment of hypertension. Lercanidipine is dihydropyridine calcium antagonist, with long duration of action and high vascular selectivity. The drug is efficient in lowering blood pressure within 24 hours, has weak cardiodepressive effect and high lipophilicity. Lercanidipine proved to be an effective and safe drug in elderly patients with hypertension, especially in patients with isolated systolic hypertension. Lercanidipine is associated with lower prevalence of leg edema in comparison with other calcium antagonists at equivalent doses.
Article Details
How to Cite
Barylski , M. (2015). Lercanidipine – 5 reasons why it is worth to use it. Medycyna Faktow (J EBM), 8(1(26), 36-39. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2321
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Kostka-Jeziorny K., Tykarski A., Dzida G. et al.: Lerkanidipina w leczeniu nadciśnienia tętniczego i jego powikłań sercowo-naczyniowych. Nadciśnienie Tętnicze 2012; 16(4): 216-223.
2. Grassi G., Seravalle G., Turri C. et al.: Short-versus longterm effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41: 558-562.
3. Borgi C.: Lercanidipine in hypertension. Vasc. Health Risk Manag. 2005; 1(3): 173-182.
4. Romito R., Pansini M.I., Perticone F. et al.: Comparitive effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J. Clin. Hypertens. 2003; 5: 249-253.
5. Cherubini A., Fabris F., Ferrari E. et al.: Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch. Gerontol. Geriatr. 2003; 37: 203-212.
6. Thuc Sinh C., Van Minh H., Van Huy T.: Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. Curr. Med. Res. Opin. 2015; 31(1): 163-170.
7. Leonetti G., Magnani B., Pessina A.C. et al.: Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. 2002; 15: 932-940.
8. Pedrinelli R., Dell’Omo G., Nuti M. et al.: Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J. Hypertens. 2003; 21: 1969-1973.
9. Lund-Johansen P., Stranden E., Helberg S. et al.: Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J. Hypertens. 2003; 21(5): 1003-1010.
10. Canavesi M., Baldini N., Leonardi A. et al.: In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J. Cardiovasc. Pharmacol. 2004; 44: 416-422.
11. Corsini A., Accomazzo M.R., Canavesi M. et al.: The new calcium antagonist lercanidipine and its enantiomers effect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press. 1998; 2: 18-22.
12. Bellosta S., Bernini F.: Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr. Atheroscler. Rep. 2000; 2: 76-81.
13. Taddei S., Virdis A., Ghiadoni L. et al.: Calcium antagonist treatment by lercanidipine prevents hyperpolarisation in essential hypertension. Hypertension 2003; 41: 950-955.
14. Fogari R., Mugellini A., Corradi L. et al.: Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients. J. Hypertens. 2000; 18(supl. 2): S65.
15. Robles N.R., Ocon J., Gomez C.F. et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27(1): 73-80.
16. Sabbatini M., Vitaioli L., Baldoni E. et al.: Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 2000; 294: 948-954.
2. Grassi G., Seravalle G., Turri C. et al.: Short-versus longterm effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41: 558-562.
3. Borgi C.: Lercanidipine in hypertension. Vasc. Health Risk Manag. 2005; 1(3): 173-182.
4. Romito R., Pansini M.I., Perticone F. et al.: Comparitive effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J. Clin. Hypertens. 2003; 5: 249-253.
5. Cherubini A., Fabris F., Ferrari E. et al.: Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch. Gerontol. Geriatr. 2003; 37: 203-212.
6. Thuc Sinh C., Van Minh H., Van Huy T.: Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. Curr. Med. Res. Opin. 2015; 31(1): 163-170.
7. Leonetti G., Magnani B., Pessina A.C. et al.: Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. 2002; 15: 932-940.
8. Pedrinelli R., Dell’Omo G., Nuti M. et al.: Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J. Hypertens. 2003; 21: 1969-1973.
9. Lund-Johansen P., Stranden E., Helberg S. et al.: Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J. Hypertens. 2003; 21(5): 1003-1010.
10. Canavesi M., Baldini N., Leonardi A. et al.: In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J. Cardiovasc. Pharmacol. 2004; 44: 416-422.
11. Corsini A., Accomazzo M.R., Canavesi M. et al.: The new calcium antagonist lercanidipine and its enantiomers effect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press. 1998; 2: 18-22.
12. Bellosta S., Bernini F.: Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr. Atheroscler. Rep. 2000; 2: 76-81.
13. Taddei S., Virdis A., Ghiadoni L. et al.: Calcium antagonist treatment by lercanidipine prevents hyperpolarisation in essential hypertension. Hypertension 2003; 41: 950-955.
14. Fogari R., Mugellini A., Corradi L. et al.: Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients. J. Hypertens. 2000; 18(supl. 2): S65.
15. Robles N.R., Ocon J., Gomez C.F. et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27(1): 73-80.
16. Sabbatini M., Vitaioli L., Baldoni E. et al.: Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 2000; 294: 948-954.